Generic placeholder image

Current Rheumatology Reviews


ISSN (Print): 1573-3971
ISSN (Online): 1875-6360

Catastrophic Antiphospholipid Syndrome - 20 Years Later

Author(s): Ignasi Rodríguez-Pintó, Gerard Espinosa and Ricard Cervera

Volume 9 , Issue 2 , 2013

Page: [73 - 80] Pages: 8

DOI: 10.2174/15733971113099990003

Price: $65


The catastrophic variant of the antiphospholipid syndrome (APS) is the most severe and acute form of APS with multiorgan involvement. Patients with this condition have the following features in common: a) clinical evidence of multiple organ involvement developed over a very short time period; b) histopathological evidence of multiple small vessel occlusions, and c) laboratory confirmation of the presence of antiphospholipid antibodies, usually in high titer.

The two key pathobiologic mechanisms that cause the clinical manifestations of catastrophic APS are the development of thrombosis and the systemic inflammatory response syndrome. A precipitating factor is reported in more than half of patients.

A combination of anticoagulants, corticosteroids, intravenous immunoglobulins and/or plasma exchanges are the treatment modalities advocated for all patients with this severe condition. Unfortunately, its mortality is still high (around 30%) despite therapy. However relapse is uncommon.

Keywords: Catastrophic antiphospholipid syndrome, antiphospholipid antibodies, anticardiolipin antibodies, lupus anticoagulant, antiphospholipid syndrome.

Rights & Permissions Print Export Cite as
© 2022 Bentham Science Publishers | Privacy Policy